Biogen confirms second PML case among Tecfidera patients

When the FDA added information about progressive multifocal leukoencephalopathy (PML) to the label of Biogen's Tecfidera last year, only one patient on the oral MS-fighter had developed the rare brain disease. Now, the Massachusetts company has confirmed another case, though this one--unlike the last--was nonfatal, a spokeswoman told MedPage Today. Story | More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.